Salmeterol - NDSRI's
References
FAQ's
References
- Skidmore, Ian Frederick; Lunts, Lawrence Henry Charles; Finch, Harry; Naylor, Alan, Phenethanolamine derivatives, Glaxo Group Ltd., United Kingdom, GB2140800A, December 5, 1984
- Kim, Kyeong Ho; Yun, Hyeong Won; Kim, Hyun Ju; Park, Hyun Ji; Choi, Pok Wah, Coupled column chromatography in chiral separation of salmeterol, Archives of Pharmacal Research Volume: 21, Issue: 2, Pages: 212-216, 1998
Frequently Asked Questions
How are Salmeterol impurities detected and quantified?
Methods such as gradient Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) and preparative HPLC can detect impurities in Salmeterol.
Can Salmeterol impurities affect patient safety?
Yes, impurities in Salmeterol can impact patient safety. Depending on their nature and concentration, contaminants can cause adverse effects or reduce the efficacy of the medication.
Which solvents help in the analysis of Salmeterol impurities
Methanol achieves optimal solubility and separation of Salmeterol impurities. However, the choice of solvent depends on the specific impurity analyzed and the analytical technique employed.
What are the temperature conditions required to store Salmeterol impurities?
Salmeterol impurities should be stored at a controlled room temperature between 2-8 ⁰C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.